Reduced expression of Raf-1 kinase inhibitory protein in renal cell carcinoma: A significant prognostic marker

Pathology

Volumn 44, Issue 6, 2012, Pages 534-539

  Moon, Ahrim ^a   Park, Jae Young ^a   Sung, Ji Youn ^a   Park, Yong Koo ^a   Kim, Youn Wha ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

Immunohistochemistry; Metastasis; Prognosis; Renal cell carcinoma; RKIP

Indexed keywords

EID: 84866890741     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32835817e8     Document Type: Article

References (33)

1. Jung KW, Won YJ, Park S, et al. Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci 2009; 24: 995-1003.
2. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-90.
3. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-8.
4. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009; 373: 1119-32.
5. Odabaei G, Chatterjee D, Jazirehi AR, et al. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res 2004; 91: 169-200.
6. Yeung K, Seitz T, Li S, et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 1999; 401: 173-7.
7. Yeung KC, Rose DW, Dhillon AS, et al. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NFkappaB activation. Mol Cell Biol 2001; 21: 7207-17.
8. Lorenz K, Lohse MJ, Quitterer U. Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 2003; 426: 574-9.
9. Zhu S, Mc Henry KT, Lane WS, Fenteany G. A chemical inhibitor reveals the role of Raf kinase inhibitor protein in cell migration. Chem Biol 2005; 12: 981-91.
10. Minoo P, Zlobec I, Baker K, et al. Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am J Clin Pathol 2007; 127: 820-7.
11. Wang J, Yang YH, Wang AQ, et al. Immunohistochemical detection of the Raf kinase inhibitor protein in nonneoplastic gastric tissue and gastric cancer tissue. Med Oncol 2010; 27: 219-23.
12. Li HZ, Gao Y, Zhao XL, et al. Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res 2009; 7: 832-40.
13. Hagan S, Al-Mulla F, Mallon E, et al. Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res 2005; 11: 7392-7.
14. Chen Y, Ouyang GL, Yi H, et al. Identification of RKIP as an invasion suppressor protein in nasopharyngeal carcinoma by proteomic analysis. J Proteome Res 2008; 7: 5254-62.
15. Li HZ, Wang Y, Gao Y, et al. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol Cancer Res 2008; 6: 917-28.
16. Kim HS, Kim GY, Lim SJ, KimYW. Loss of Raf-1 kinase inhibitory protein in pancreatic ductal adenocarcinoma. Pathology 2010; 42: 655-60.
17. Kim HS, Kim GY, Lim SJ, Kim YW. Raf-1 kinase inhibitory protein expression in thyroid carcinomas. Endocr Pathol 2010; 21: 253-7.
18. Kim HS, Kim GY, Lim SJ, Park YK, Kim YW. Reduced expression of Raf- 1 kinase inhibitory protein is a significant prognostic marker in patients with gallbladder carcinoma. Hum Pathol 2010; 41: 1609-16.
19. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC Cancer Staging Manual. 7th ed. Springer: New York, 2010.
20. Kim HS, Kim GY, Lim SJ, Kim YW. Loss of Raf-1 kinase inhibitory protein in pancreatic ductal adenocarcinoma. Pathology 2010; 42: 655-60.
21. Kim HS, Kim GY, Lim SJ, Park YK, Kim YW. Reduced expression of Raf- 1 kinase inhibitory protein is a significant prognostic marker in patients with gallbladder carcinoma. Hum Pathol 2010; 41: 1609-16.
22. Al-Mulla F, Hagan S, Al-Ali W, et al. Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability. J Clin Pathol 2008; 61: 524-9.
23. Al-Mulla F, Hagan S, Behbehani AI, et al. Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol 2006; 24: 5672-9.
24. Schuierer MM, Bataille F, Hagan S, KolchW, Bosserhoff AK. Reduction in Raf kinase inhibitor protein expression is associated with increased Rasextracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 2004; 64: 5186-92.
25. Fu Z, Kitagawa Y, Shen R, et al. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate 2006; 66: 248-56.
26. Chatterjee D, Sabo E, Tavares R, Resnick MB. Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clin Cancer Res 2008; 14: 2994-3001.
27. Schuierer MM, Bataille F, Weiss TS, Hellerbrand C, Bosserhoff AK. Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep 2006; 16: 451-6.
28. Martinho O, Gouveia A, Silva P, et al. Loss of RKIP expression is associated with poor survival in GISTs. Virchows Arch 2009; 455: 277-84.
29. Beach S, Tang H, Park S, et al. Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene 2008; 27: 2243-8.
30. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-54.
31. Mikami S, Katsube KI, Oya M, et al. Expression of Snail and Slug in renal cell carcinoma: E-cadherin repressor Snail is associated with cancer invasion and prognosis. Lab Invest 2011; 91: 1443-58.
32. Arranz JA, Climent MA, Gonzalez-Larriba JL, Leon L, Maroto JP. Sorafenib in renal cell carcinoma. Crit Rev Oncol Hematol 2011; 80: 314-22.
33. Zeng L, Imamoto A, Rosner MR. Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target. Expert Opin Ther Targets 2008; 12: 1275-87.